The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | The next steps for the IDH2 inhibitor drug enasidenib
The IDH2 inhibitor drug, enasidenib has previously only been administered to elderly populations with acute myeloid leukemia. Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses why this is the case, as well as the next steps for the drug. This includes further Phase II and III trials in all age groups to determine the efficiency of combination therapies. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
